NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.
Chinnadurai S, Snyder K, Sathe N, et al. Diagnosis and Management of Infantile Hemangioma [Internet]. Rockville (MD): Agency for Healthcare Research and Quality (US); 2016 Jan. (Comparative Effectiveness Reviews, No. 168.)
Tablet H-6Common Adverse Events Reported in >1% of Patients
| Zyclara® 3.75% (n=400) | Zyclara® 2.5% (n=379) | |
|---|---|---|
| Application site pain | 28 (7.0%) | 20 (5.3%) |
| Application site irritation | 24 (6.0%) | 13 (3.4%) |
| Nasopharyngitis | 16 (4.0%) | 21 (5.5%) |
| Upper respiratory tract infection | 12 (3.0%) | 7 (1.8%) |
| Application site pruritus | 11 (2.8%) | 17 (4.5%) |
| Headache | 9 (2.3%) | 8 (2.1%) |
| Vaginitis bacterial | 8 (2.0%) | 6 (1.6%) |
| Nausea | 7 (1.8%) | 4 (1.1%) |
| Back pain | 7 (1.8%) | 4 (1.1%) |
| Urinary tract infection | 6 (1.5%) | 6 (1.6%) |
| Sinusitis | 6 (1.5%) | 4 (1.1%) |
| Sinus congestion | 6 (1.5%) | 1 (0.3%) |
| Cough | 5 (1.3%) | 5 (1.3%) |
| Rash | 5 (1.3%) | 2 (0.5%) |
| Vomiting | 5 (1.3%) | 1 (0.3%) |
| Skin laceration | 5 (1.3%) | 1 (0.3%) |
- Tablet H-6, Common Adverse Events Reported in >1% of Patients - Diagnosis and Ma...Tablet H-6, Common Adverse Events Reported in >1% of Patients - Diagnosis and Management of Infantile Hemangioma
Your browsing activity is empty.
Activity recording is turned off.
See more...